Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 534-540

  Seaman, Vincent ^a   Jumaan, Aisha ^a   Yanni, Emad ^a   Lewis, Brian ^a   Neyer, Jonathan ^a   Roda, Paul ^b   Xu, Mingjiang ^c,d   Hoffman, Ronald ^c,d  

^a AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY   (United States)

^b Geisinger/Hazleton Cancer Center   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COAL; JANUS KINASE 2;

ADULT; AGED; ARTICLE; COAL MINING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENVIRONMENTAL FACTOR; FEMALE; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; UNITED STATES; WORLD HEALTH ORGANIZATION;

FEMALE; HUMANS; INCIDENCE; INTERVIEWS AS TOPIC; JANUS KINASE 2; MALE; MIDDLE AGED; PENNSYLVANIA; POISSON DISTRIBUTION; POLYCYTHEMIA VERA; QUESTIONNAIRES; REGISTRIES;

EID: 60549112374     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0922     Document Type: Article

References (36)

1. Berlin N. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-51.
2. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007;109:5104-11.
3. Mesa RA, Verstovsek S, Cervantes F, et al.; for the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007;31:737 -40.
4. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673 - 83.
5. James C, Delhommeau F, Marzac C, et al. Detection of JAK2V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006;20: 350-53.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7: 387-97.
8. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis:
9. recommendations from an Ad hoc International Expert Panel. Blood 2007;110:1092-97.
10. Tefferi A, Pardanani A. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc 2007;82:599-604.
11. 617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006;108:346-52.
12. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992;7:251-55.
13. Modan B, Kallner H, Zemer D, Yoran C. A note on the increased risk of polycythemia vera in Jews. Blood 1971;37:172-6.
14. Caldwell GG, Kelley DB, Heath CW, Jr., Zack M. Polycythemia vera among participants of a nuclear weapons test. JAMA 1984;252:662 -64.
15. Hayes RB, Blair A, Stewart PA, Herrick RF, Mahar H. Mortality of U.S. embalmers and funeral directors. Am J Ind Med 1990;18:641 -52.
16. Kaplan SD. Update of a mortality study of workers in petroleum refineries. J Occup Med 1986;28:514-6.
17. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008;83:359-62.
18. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:171-3.
19. Phekoo KJ, Richards MA, Møller H, Schey SA; for the South Thames Haematology Specialist Committee. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006;91:1400-04.
20. Johansson P, Kutti J, Andréasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med 2004;256:161-65.
21. Ridell B, Carneskog J, Wedel H, et al. Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992. Eur J Haematol 2000;65:267-71.
22. Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematology Cell Therapy 1998;40:159-65.
23. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 2007;109:339-42.
24. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001;49:164-66.
25. Anía BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 1994;47: 89 -93.
26. Ruiz-Argüelles GJ, López-Martínez B, Lobato-Mendizábal E, Ruiz-Delgado GJ. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos. Int J Hematol 2002;75:499-502.
27. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999;61:10-5.
28. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128-34.
29. Liu G, Niu Z, Van iekerk D, Xue J, Zheng L. Polycyclic aromatic hydrocarbons (PAHs) from coal combustion: emissions, analysis, and toxicology. Rev Environ Contam Toxicol 2008;192:1-28.
30. V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera. Am J Hematol 2007;82: 80-2.
31. Sakai R, Kajiume T, Inoue H, Kanno R, Miyazaki M, Ninomiya Y, Kanno M. TCDD treatment eliminates the long-term reconstitution activity of hematopoietic stem cells. Toxicol Sci 2003;72:84-91.
32. van Grevenynghe J, Bernard M, Langouet S, Le Berre C, Fest T, Fardel O. Human CD34-positive hematopoietic stem cells constitute targets for carcinogenic polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther 2005;314:693-702.
33. Garrett RW, Gasiewicz TA. The aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin alters the circadian rhythms, quiescence, and expression of clock genes in murine hematopoietic stem and progenitor cells. Exp Hematol 2006;69:2076-83.
34. + cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol 2007;35:1633-40.
35. Badham HJ, Winn LM. Investigating the role of the aryl hydrocarbon receptor in benzene-initiated toxicity in vitro. Toxicology 2007;229: 177-85.
36. Hayashibara T, Yamada Y, Mori N, et al. Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 2003;300:128-34.